The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer

Abstract Background Despite recent advances in treating non‐small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK‐positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK‐positive NSCLC. Methods Between 2011 and 2018, a total...

Full description

Bibliographic Details
Main Authors: Ja Yoon Heo, Changhee Park, Bhumsuk Keam, Chan‐Young Ock, Miso Kim, Tae Min Kim, Dong‐Wan Kim, Se Hyun Kim, Yu Jung Kim, Jong Seok Lee, Dae Seog Heo
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Thoracic Cancer
Subjects:
Anaplastic lymphoma kinase
immune checkpoint inhibitors
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.13195

Internet

https://doi.org/10.1111/1759-7714.13195

Similar Items